Can measuring drug levels reduce chemo side effects in leukemia patients?

NCT ID NCT07254312

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how much venetoclax is in the blood of people with acute myeloid leukemia (AML) who are in remission and still receiving treatment. The goal is to see if higher drug levels are linked to more severe side effects, like low white blood cell counts. By understanding this, doctors hope to adjust doses to make treatment safer and more tolerable. The study will enroll 14 participants and measure venetoclax levels using a special lab test.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax
What this could lead to: If successful, this could help doctors personalize venetoclax dosing to reduce severe side effects while keeping leukemia in remission.
What could go wrong: This is a very small, early observational study with only 14 participants. It is not testing a new treatment, so it may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA)

Contacts and locations

Locations

Fondazione IRCCS Policlinico San Matteo, SC Oncologia
RECRUITING

Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.